Remove FDA Compliance Remove Marketing Remove Regulation
article thumbnail

What the FDA’s Draft Guidance for AI-Enabled Medical Devices Means

XTalks

Fundamentally, the guidance brings forth the importance of a Total Product Lifecycle (TPLC) approach, a comprehensive strategy that considers every stage of a device’s journey design, development, market approval and real-world use to ensure long-term safety and effectiveness. Another key area is data management.

article thumbnail

What Does Google’s Move to Responsive Search Ads for Paid Search Mean for Pharma?

Intouch Solutions

Let’s talk about what that means for pharma marketers! Why Pharma Marketers Should Care About RSAs RSAs are a text ad format that requires an increased number of headline and description line variations than ETAs require. Among the concerns that pharma marketers face: The RSA ad format will be new to most MLR reviewers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA End-of-Year Release of Warning Letters Impresses (or Depresses)

FDA Law Blog

Four of the letters addressed failure to comply with drug Current Good Manufacturing Practice regulations, four more stated that the recipients were distributing unapproved drug products, two alleged violations of the Quality System Regulation by medical device manufacturers, and one was addressed to a clinical investigator.

article thumbnail

Comprehensive Guide to Medical Device Safety, Systems, and Regulatory Compliance: FAQ

Cloudbyz

Introduction to Medical Device Safety, Systems, and Regulations The medical device industry is a rapidly evolving field that plays a critical role in modern healthcare. This is where the importance of stringent safety processes, robust systems, and comprehensive regulations comes into play. What is the Medical Device Safety process?

article thumbnail

FDA Flips It and Reverses It: FDA Withdraws HHS Withdrawal of UDI Guidance

FDA Law Blog

Koblitz — While typically, FDA is responsible for setting forth its own agenda and enforcing compliance with its own regulations, the Trump Administration’s HHS, on its way out the door in late 2020 , took the unusual steps of withdrawing an important FDA Compliance Policy Guide, “Marketed Unapproved Drugs – Compliance Policy Guide Sec.